Citius Sets Up Access to Lymphir in Southern Europe
MT Newswires Live
Oct 07
Citius Oncology (CTOR) said Tuesday it has entered into an exclusive distribution agreement with Greece-based Integris Pharma to make Lymphir available in Southern Europe.
The partnership coverage includes Greece, Cyprus, Malta, Bulgaria, and Romania, it said. Lymphir is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma.
The deal is part of its Named Patient Programs, also known as early access programs, Citius said, adding that it is in discussions with distribution partners to make the drug available through the program in Europe, South America and the Middle East.
Price: 1.90, Change: +0.03, Percent Change: +1.66
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.